Natixis’s AbbVie ABBV Stock Holding History

Natixis’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-348	Closed	-$47K	–	1070
2022 Q3	$47K	Buy	348 +12	+4%	+$1.72K	﹤0.01%	1009
2022 Q2	$51K	Buy	+336	New	+$51.3K	﹤0.01%	1072

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Natixis's ABBV Position: Q1 2026 in Review

Natixis reduced its AbbVie (ABBV) stake by 32% in Q1 2026, selling an estimated $24.9M and leaving 233,196 shares worth $50.7M. The position accounts for 0.18% of the portfolio, ranked #78.

Natixis first reported a position in ABBV in Q2 2013 and has held it in 49 quarters since. The position peaked at $199M in Q3 2018. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Natixis held 233,196 shares of AbbVie worth $50.7M as of Q1 2026.
Natixis sold 112,180 AbbVie shares in Q1 2026, an estimated $24.9M.
AbbVie made up 0.18% of Natixis's portfolio in Q1 2026, its #78 holding.
Natixis first reported a position in AbbVie in Q2 2013 and has held it in 49 quarters since.
Natixis's AbbVie position peaked at $199M in Q3 2018.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.